TFE3/TFEB translocation renal cell carcinoma(TFE3/TFEB tRCC)occupies a prominent position in the molecular pathological classification of renal cancers due to its distinctive genetic abnormalities and its clinical pre-dilection for younger patients.Over nearly two decades of research,the spectrum of TFE3/TFEB fusion partner genes has expanded,highlighting the increasing morphological heterogeneity of TFE3/TFEB tRCC.This article reviews the clinicopathological and molecular features of TFE3/TFEB tRCC,emphasizing the associations between the major fusion subtypes and their morphological manifestations as well as immunophenotypes.Additionally,the practical value of an-cillary diagnostic techniques,such as molecular testing,is summarized,aiming to provide a reference for the routine and differential diagnosis of TFE3/TFEB tRCC.

Humans ; Class I Phosphatidylinositol 3-Kinases/genetics* ; Breast Neoplasms/diagnosis* ; Mutation ; Female ; China ; DNA Mutational Analysis/methods* ; Genetic Testing/standards*

Humans ; Colorectal Neoplasms/pathology* ; Pathology, Molecular/methods* ; Biomarkers, Tumor/genetics* ; Genetic Testing ; China

Humans ; Glioma/metabolism* ; Consensus ; China ; Brain Neoplasms/pathology* ; Pathology, Molecular

Humans ; Ovarian Neoplasms/metabolism* ; Female ; Biomarkers, Tumor/metabolism* ; Mutation

Humans ; Consensus ; High-Throughput Nucleotide Sequencing/standards* ; Neoplasms/diagnosis* ; Quality Control ; Sequence Analysis, DNA/methods* ; Sequence Analysis, RNA/methods*

Humans ; Thyroid Neoplasms/metabolism* ; Consensus ; Thyroidectomy ; China ; Immunohistochemistry ; Postoperative Period

Humans ; Biomarkers, Tumor/metabolism* ; Claudins/analysis* ; Consensus ; Immunohistochemistry/methods* ; Stomach Neoplasms/diagnosis*

Humans ; Ovarian Neoplasms/drug therapy* ; Folate Receptor 1/metabolism* ; Female ; Immunohistochemistry/standards* ; Consensus ; Biomarkers, Tumor/metabolism* ; Fallopian Tube Neoplasms/pathology*

Claudin18.2 is a member of the tight junction protein family,which can be abnormally expressed in a variety of malignant solid tumors,including gastric cancer.The drug therapy targeting Claudin18.2 has been a hot top-ic in recent years,making Claudin18.2 protein detection an important means of screening for tumor therapy.In this re-view,the clinical pathological detection methods,interpretation criteria,and expression research status of Claudin18.2 protein in various malignant solid tumors are reviewed,aiming to provide new ideas for tumor detection and treatment based on Claudin18.2 protein.